1. Home
  2. MITK vs GYRE Comparison

MITK vs GYRE Comparison

Compare MITK & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mitek Systems Inc.

MITK

Mitek Systems Inc.

HOLD

Current Price

$15.36

Market Cap

686.5M

Sector

Technology

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.18

Market Cap

679.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITK
GYRE
Founded
1983
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
686.5M
679.4M
IPO Year
1995
2004

Fundamental Metrics

Financial Performance
Metric
MITK
GYRE
Price
$15.36
$7.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$15.00
$17.00
AVG Volume (30 Days)
966.5K
46.7K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
171.43
N/A
EPS
0.06
0.02
Revenue
$45,390,000.00
$275,000.00
Revenue This Year
$9.55
$19.88
Revenue Next Year
$8.07
N/A
P/E Ratio
$255.17
$403.25
Revenue Growth
N/A
N/A
52 Week Low
$8.53
$6.58
52 Week High
$15.80
$11.77

Technical Indicators

Market Signals
Indicator
MITK
GYRE
Relative Strength Index (RSI) 60.17 41.49
Support Level $13.33 $6.87
Resistance Level $15.70 $8.28
Average True Range (ATR) 0.62 0.34
MACD 0.10 -0.02
Stochastic Oscillator 85.25 6.98

Price Performance

Historical Comparison
MITK
GYRE

About MITK Mitek Systems Inc.

Mitek Systems Inc is engaged in the development, sale, and service of proprietary software solutions related to mobile imaging. The firm is a software development company with expertise in artificial intelligence, and machine learning. It serves more than 7,900 financial services organizations, financial technology (fintech) brands, telecommunications companies, and marketplace brands across the globe. The company's Mobile Deposit solution is used by consumers for mobile check deposits. The company's Mobile Verify verifies a user's identity online, enabling organizations to build safer digital communities, whereas CheckReader enables financial institutions to automatically extract data from a check image received across any deposit channel - branch, ATM, RDC, and mobile.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: